SPY334.33+2.22 0.67%
DIA273.90+1.90 0.70%
IXIC11,108.07+109.67 1.00%

Wedbush Downgrades CytomX Therapeutics to Neutral, Lowers Price Target to $8

Wedbush downgrades CytomX Therapeutics (NASDAQ:CTMX) from Outperform to Neutral and lowers the price target from $25 to $8.

Benzinga · -

Wedbush downgrades CytomX Therapeutics (NASDAQ:CTMX) from Outperform to Neutral and lowers the price target from $25 to $8.